Justin T Sorge1, Matthew Young2,3, Bridget Maloney-Hall2, Adam Sherk4, Pam Kent2, Jinhui Zhao4, Tim Stockwell4,5, Katerina Perlova4, Scott Macdonald4,6, Brian Ferguson7. 1. Canadian Institute for Substance Use Research, Technology Enterprise Facility, Room 273, University of Victoria, Victoria, British Columbia, V8P 5C2, Canada. justinsorge@uvic.ca. 2. Canadian Centre on Substance Use and Addiction, Ottawa, Ontario, Canada. 3. Department of Psychology, Carleton University, Ottawa, Ontario, Canada. 4. Canadian Institute for Substance Use Research, Technology Enterprise Facility, Room 273, University of Victoria, Victoria, British Columbia, V8P 5C2, Canada. 5. Department of Psychology, University of Victoria, Victoria, British Columbia, Canada. 6. School of Health and Information Sciences, University of Victoria, Victoria, British Columbia, Canada. 7. Department of Economics, University of Guelph, Guelph, Ontario, Canada.
Abstract
OBJECTIVE: Policy makers require evidence-based estimates of the economic costs of substance use-attributable lost productivity to set strategies aimed at reducing substance use-related harms. Building on a study by Rehm et al. (2006), we provide estimates of workplace costs using updated methods and data sources. METHODS: We estimated substance use-attributable productivity losses due to premature mortality, long-term disability, and presenteeism/absenteeism in Canada between 2007 and 2014. Lost productivity was estimated using a hybrid prevalence and incidence approach. Substance use prevalence data were drawn from three national self-report surveys. Premature mortality data were from the Canadian Vital Statistics Death Database, and long-term disability and workplace interference data were from the Canadian Community Health Survey. RESULTS: In 2014, the total cost of lost productivity due to substance use was $15.7 billion, or approximately $440 per Canadian, an increase of 8% from 2007. Substances responsible for the greatest economic costs were alcohol (38% of per capita costs), tobacco (37%), opioids (12%), other central nervous system (CNS) depressants (4%), other CNS stimulants (3%), cannabis (2%), cocaine (2%), and finally other psychoactive substances (2%). CONCLUSION: In 2014, alcohol and tobacco represent three quarters of substance use-related lost productivity costs in Canada, followed by opioids. These costs provide a valuable baseline that can be used to assess the impact of future substance use policy, practice, and other interventions, especially important given Canada's opioid crisis and recent cannabis legalization.
OBJECTIVE: Policy makers require evidence-based estimates of the economic costs of substance use-attributable lost productivity to set strategies aimed at reducing substance use-related harms. Building on a study by Rehm et al. (2006), we provide estimates of workplace costs using updated methods and data sources. METHODS: We estimated substance use-attributable productivity losses due to premature mortality, long-term disability, and presenteeism/absenteeism in Canada between 2007 and 2014. Lost productivity was estimated using a hybrid prevalence and incidence approach. Substance use prevalence data were drawn from three national self-report surveys. Premature mortality data were from the Canadian Vital Statistics Death Database, and long-term disability and workplace interference data were from the Canadian Community Health Survey. RESULTS: In 2014, the total cost of lost productivity due to substance use was $15.7 billion, or approximately $440 per Canadian, an increase of 8% from 2007. Substances responsible for the greatest economic costs were alcohol (38% of per capita costs), tobacco (37%), opioids (12%), other central nervous system (CNS) depressants (4%), other CNS stimulants (3%), cannabis (2%), cocaine (2%), and finally other psychoactive substances (2%). CONCLUSION: In 2014, alcohol and tobacco represent three quarters of substance use-related lost productivity costs in Canada, followed by opioids. These costs provide a valuable baseline that can be used to assess the impact of future substance use policy, practice, and other interventions, especially important given Canada's opioid crisis and recent cannabis legalization.
Entities:
Keywords:
Burden of disease; Cost of illness; Harms; Lost productivity; Substance use
Authors: Louisa Degenhardt; Harvey A Whiteford; Alize J Ferrari; Amanda J Baxter; Fiona J Charlson; Wayne D Hall; Greg Freedman; Roy Burstein; Nicole Johns; Rebecca E Engell; Abraham Flaxman; Christopher J L Murray; Theo Vos Journal: Lancet Date: 2013-08-29 Impact factor: 79.321
Authors: Alison M Pearce; Paul Hanly; Aileen Timmons; Paul M Walsh; Ciaran O'Neill; Eleanor O'Sullivan; Rachael Gooberman-Hill; Audrey Alforque Thomas; Pamela Gallagher; Linda Sharp Journal: Appl Health Econ Health Policy Date: 2015-08 Impact factor: 2.561
Authors: Louisa Degenhardt; Fiona Charlson; Jeff Stanaway; Sarah Larney; Lily T Alexander; Matthew Hickman; Benjamin Cowie; Wayne D Hall; John Strang; Harvey Whiteford; Theo Vos Journal: Lancet Infect Dis Date: 2016-09-21 Impact factor: 25.071